A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis.
Phase of Trial: Phase II
Latest Information Update: 17 Oct 2017
At a glance
- Drugs SRT 2104 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 17 Feb 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
- 17 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.